Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aligos Therapeutics Inc (NQ: ALGS )

1.750 -0.170 (-8.85%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 184,461
Open 1.880
Bid (Size) 1.770 (1)
Ask (Size) 1.900 (6)
Prev. Close 1.920
Today's Range 1.750 - 1.910
52wk Range 0.8401 - 3.170
Shares Outstanding 42,815,593
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Celyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga

Performance

YTD
+86.17%
+86.17%
1 Month
+86.17%
+86.17%
3 Month
+76.77%
+76.77%
6 Month
+16.67%
+16.67%
1 Year
-40.48%
-40.48%

More News

Read More
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Aligos Co-Founders File Complaint Against Johnson & Johnson Alleging Fraud
Via Benzinga
Where Aligos Therapeutics Stands With Analysts
Via Benzinga
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
From Aligos Therapeutics
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
Via Benzinga
Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi DART Meeting
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD’s The Liver Meeting® 2022
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022
From Aligos Therapeutics
Via Globe NewsWire
SVB Leerink Maintains Market Perform Rating for Aligos Therapeutics: Here's What You Need To Know
Via Benzinga
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting® 2022
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics to Announce Third Quarter Results November 2, 2022
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics Files Response to Janssen Biopharma Lawsuit and Lodges Counterclaims Alleging Unfair Competition and Promissory Fraud
From Aligos Therapeutics
Via Globe NewsWire
Aligos Therapeutics's Return On Capital Employed Overview
Via Benzinga
Aligos Therapeutics Earnings Preview
Via Benzinga
Aligos Therapeutics to Announce Second Quarter 2022 Results August 4, 2022
From Aligos Therapeutics
Via Globe NewsWire
Aligos Shares Fall Following Commencement Of Initial-Stage Chronic Hepatitis B Study
Via Benzinga
Aligos Therapeutics's Return On Capital Employed Insights
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.